These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 26917708)

  • 1. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
    Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
    J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model.
    Song IH; Noh Y; Kwon J; Jung JH; Lee BC; Kim KI; Lee YJ; Kang JH; Rhee CS; Lee CH; Lee TS; Choi IJ
    Oncotarget; 2017 Nov; 8(54):92090-92105. PubMed ID: 29190900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
    Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
    Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cumulated Activity Comparison of
    Laffon E; Thumerel M; Jougon J; Marthan R
    J Nucl Med; 2017 Jun; 58(6):888-890. PubMed ID: 28082435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
    Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X
    Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
    Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
    J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model.
    Song IH; Jeong MS; Hong HJ; Shin JI; Park YS; Woo SK; Moon BS; Kim KI; Lee YJ; Kang JH; Lee TS
    Clin Cancer Res; 2019 Oct; 25(20):6148-6159. PubMed ID: 31337646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma Models.
    Lee TS; Song IH; Shin JI; Park YS; Kim JY; Kim KI; Lee YJ; Kang JH
    Cells; 2018 Oct; 7(11):. PubMed ID: 30373221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
    Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
    Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 177Lu-DO3A-HSA-Z EGFR:1907: characterization as a potential radiopharmaceutical for radionuclide therapy of EGFR-expressing head and neck carcinomas.
    Hoppmann S; Qi S; Miao Z; Liu H; Jiang H; Cutler CS; Bao A; Cheng Z
    J Biol Inorg Chem; 2012 Jun; 17(5):709-18. PubMed ID: 22418921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer.
    Yamaguchi A; Achmad A; Hanaoka H; Heryanto YD; Bhattarai A; Ratianto ; Khongorzul E; Shintawati R; Kartamihardja AAP; Kanai A; Sugo Y; S Ishioka N; Higuchi T; Tsushima Y
    BMC Cancer; 2019 Oct; 19(1):1000. PubMed ID: 31651282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of chelator type on in vitro receptor binding and stability in 177Lu-labeled cetuximab and panitumumab.
    Novy Z; Laznickova A; Mandikova J; Barta P; Laznicek M; Trejtnar F
    J Labelled Comp Radiopharm; 2014 Jun; 57(7):448-52. PubMed ID: 24889367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential.
    Koi L; Bergmann R; Brüchner K; Pietzsch J; Pietzsch HJ; Krause M; Steinbach J; Zips D; Baumann M
    Radiother Oncol; 2014 Feb; 110(2):362-9. PubMed ID: 24440046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of Secreted Extracellular Periostin, an Important Marker of Invasion in the Tumor Microenvironment in Esophageal Cancer.
    Heidari P; Esfahani SA; Turker NS; Wong G; Wang TC; Rustgi AK; Mahmood U
    J Nucl Med; 2015 Aug; 56(8):1246-51. PubMed ID: 26069303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
    J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring pitfalls of
    Striese F; Sihver W; Gao F; Bergmann R; Walther M; Pietzsch J; Steinbach J; Pietzsch HJ
    Amino Acids; 2018 Oct; 50(10):1415-1431. PubMed ID: 30039310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.
    Hoeben BA; Molkenboer-Kuenen JD; Oyen WJ; Peeters WJ; Kaanders JH; Bussink J; Boerman OC
    Int J Cancer; 2011 Aug; 129(4):870-8. PubMed ID: 20957635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Tumor Pretargeting System Based on Complementary l-Configured Oligonucleotides.
    Schubert M; Bergmann R; Förster C; Sihver W; Vonhoff S; Klussmann S; Bethge L; Walther M; Schlesinger J; Pietzsch J; Steinbach J; Pietzsch HJ
    Bioconjug Chem; 2017 Apr; 28(4):1176-1188. PubMed ID: 28222590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
    Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
    Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.